Profiel
Fernando Doñate worked as the Director of Preclinical Research at Proacta, Inc. from 2008 to 2010.
He also worked as the Associate Director of Biology at Attenuon, LLC.
Dr. Doñate earned a doctorate degree from the University of Missouri in 1994 and an undergraduate degree from Universidad Complutense de Madrid in 1988.
Eerdere bekende functies van Fernando Doñate
Bedrijven | Functie | Einde |
---|---|---|
Attenuon, LLC | Corporate Officer/Principal | - |
Proacta, Inc.
Proacta, Inc. BiotechnologyHealth Technology Proacta, Inc. develops drugs to treat cancer. It is developing a new generation of hypoxia-activated prodrug compounds to treat cancer. The firm’s lead product PR610, is a proprietary, hypoxia-activated prodrug with potential antineoplastic activity. The company was founded in 2001 by William A. Denny, Amato J. Giaccia, William Robert Wilson and Martin J. Brown and is headquartered in La Jolla, CA. | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Fernando Doñate
University of Missouri | Doctorate Degree |
Universidad Complutense de Madrid | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
Proacta, Inc.
Proacta, Inc. BiotechnologyHealth Technology Proacta, Inc. develops drugs to treat cancer. It is developing a new generation of hypoxia-activated prodrug compounds to treat cancer. The firm’s lead product PR610, is a proprietary, hypoxia-activated prodrug with potential antineoplastic activity. The company was founded in 2001 by William A. Denny, Amato J. Giaccia, William Robert Wilson and Martin J. Brown and is headquartered in La Jolla, CA. | Health Technology |
Attenuon, LLC |